Effective Tumor Labeling of Pancreatic Cancer in a Patient Derived Orthotopic Xenograft Mouse Model using Fluorescent Humanized Anti-CEA Antibody

Thinzar M. Lwin, MS MD

Takashi Murakami, MD, Paul J. Yazaki, PhD, Bryan Clary, MD, Robert M. Hoffman, Ph.D., Michael Bouvet, MD
Margins in Oncologic Surgery
Tumor Specific Fluorescence

Probe

Target

Fluorophore

Humanized anti-CEA antibody

Human Carcinoembryonic Antigen

IRDye® 800CW NHS Ester

C_{n+2}H_{n+1}N_{n+1}NaO_{n+1}S_{n+1}

Exact Mass: 1165.20291

Mol. Wt.: 1166.20297
Selective Tumor Labeling of Pancreatic Cancer by Anti-CEA-IRDye800
M5A-LICOR-IR800 in a Patient Derived Orthotopic Xenograft Model (PDOX)
Features

• Humanized anti-CEA antibody
• IRDye800
• Patient derived orthotopic xenograft of pancreatic cancer
• Bright and specific in-situ entire tumor labeling
• Potential for tumor-specific fluorescence guided surgery
Acknowledgements

UC San Diego
Moores Cancer Center

UCSD, Cancer Therapeutics Training Program:
T32 CA 121938-10

Dr Michael Bouvet
UCSD, Moores Cancer Cancer

Dr Robert Hoffman
Anticancer Inc.

Dr Paul Yazaki
City of Hope, Beckman Research Institute

Dr Jonathan de Long
UCSD, Bouvet lab & Center for Future of Surgery

Dr Steven Dowdy
UCSD, Cellular and Molecular Medicine

Dr Stephen Howell
UCSD, Moores Cancer Center
CT2 Program Director